Fig. 3From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabA Overall survival and B progression-free survival in patients with type 2 diabetes according to blood glucose level at baseline. Glucose level was classified as high when > 137 mg/dlBack to article page